H. K. Brown, K. Schiavone, F. Gouin, M. F. Heymann, and D. Heymann, Biology of Bone Sarcomas and New Therapeutic Developments, Calcif Tissue Int, vol.102, pp.174-195, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01653600

A. J. Mutsaers and C. R. Walkley, Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells, Bone, vol.62, pp.56-63, 2014.

N. Tang, W. X. Song, J. Luo, R. C. Haydon, and T. C. He, Osteosarcoma development and stem cell differentiation, Clin Orthop Relat Res, vol.466, pp.2114-2144, 2008.

A. B. Mohseny, K. Szuhai, S. Romeo, E. P. Buddingh, I. Briaire-de-bruijn et al., Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2, J Pathol, vol.219, pp.294-305, 2009.

M. Cortini, S. Avnet, and N. Baldini, Mesenchymal stroma: Role in osteosarcoma progression, Cancer Lett, vol.405, pp.90-99, 2017.

A. Alfranca, L. Martinez-cruzado, J. Tornin, A. Abarrategi, T. Amaral et al., Bone microenvironment signals in osteosarcoma development, Cell Mol Life Sci, vol.72, pp.3097-113, 2015.

M. F. Heymann, F. Lézot, and D. Heymann, The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma, Cell Immunol
URL : https://hal.archives-ouvertes.fr/inserm-01644725

C. Dumars, J. M. Ngyuen, A. Gaultier, R. Lanel, N. Corradini et al., Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, pp.78343-78354, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466103

S. Théoleyre, K. Mori, B. Cherrier, N. Passuti, F. Gouin et al., Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma, BMC Cancer, vol.5, p.123, 2005.

M. F. Heymann, H. K. Brown, and D. Heymann, Drugs in early clinical development for the treatment of osteosarcoma, Expert Opin Investig Drugs, vol.25, pp.1265-1280, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466096

H. K. Brown, M. Tellez-gabriel, and D. Heymann, Cancer stem cells in osteosarcoma, Cancer Lett, vol.386, pp.189-195, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01466078

M. Najafi, B. Farhood, and K. Mortezaee, Cancer stem cells (CSCs) in cancer progression and therapy, J Cell Physiol

E. Reimann, S. Kõks, X. D. Ho, K. Maasalu, and A. Märtson, Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data, Hum Genomics, vol.8, p.20, 2014.

H. , S. L. Li, H. Wu, Y. Teng, W. Wang et al., Epigenetic regulation of CXCL12 plays a critical role in mediating tumor progression and the immune response in osteosarcoma, Cancer Res, vol.78, pp.3938-3953, 2018.

M. López-lázaro, The stem cell division theory of cancer, Crit Rev Oncol Hematol, vol.123, pp.95-113, 2018.

M. Murase, M. Kano, T. Tsukahara, A. Takahashi, T. Torigoe et al., Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas, British J Cancer, vol.101, pp.1425-1432, 2009.

M. Yang, M. Yan, R. Zhang, J. Li, and Z. Luo, Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells, Cancer Sci, vol.102, pp.1774-81, 2011.

A. Halldorsson, S. Brooks, S. Montgomery, and S. Graham, Lung metastasis 21 years after initial diagnosis of osteosarcoma: a case report, J Med Case Rep, vol.3, p.9298, 2009.

P. Perrot, J. Rousseau, A. L. Bouffaut, F. Rédini, E. Cassagnau et al., Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence, PLoS One, vol.5, p.10999, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00667931

U. Basu-roy, E. Seo, L. Ramanathapuram, T. B. Rapp, J. A. Perry et al., Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas, Oncogene, vol.31, pp.2270-2282, 2012.

U. Basu-roy, N. S. Bayin, K. Rattanakorn, E. Han, D. G. Placantonakis et al., Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells, Nature Commun, vol.6, p.6411, 2015.

K. Honoki, H. Fujii, A. Kubo, A. Kido, T. Mori et al., Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance, Oncol Rep, vol.24, pp.501-5015, 2010.

N. Greco, T. Schott, X. Mu, A. Rothenberg, C. Voigt et al., ALDH activity correlates with metastatic potential in primary sarcomas of bone, J Cancer Ther, vol.5, pp.331-338, 2014.

L. Wang, P. Park, H. Zhang, L. Marca, F. Lin et al., Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity, J Cancer, vol.128, pp.294-303, 2011.

A. M. Guth, M. Deogracias, and S. W. Dow, Comparison of cancer stem cell antigen expression by tumor cell lines and by tumor biopsies from dogs with melanoma and osteosarcoma, Vet Immunol Immunopathol, vol.161, pp.132-140, 2014.

A. He, X. Yang, Y. Huang, T. Feng, Y. Wang et al., , p.133, 2015.

, CD44(+) Cells Mediate in the Lung Metastasis of Osteosarcoma, J Cell Biochem, vol.116, pp.1719-1729

A. S. Dhikari, N. Agarwal, B. M. Wood, C. Porretta, B. Ruiz et al., CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance, Cancer Res, vol.70, pp.4602-4612, 2010.

V. Tirino, V. Desiderio, R. Aquino, D. Francesco, F. Pirozzi et al., Detection and characterization of CD133+ cancer stem cells in human solid tumours, PloS one, vol.3, p.3469, 2008.

V. Tirino, V. Desiderio, F. Paino, D. Rosa, A. Papaccio et al., Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo, FASEB J, vol.25, pp.2022-2030, 2011.

A. He, W. Qi, Y. Huang, T. Feng, J. Chen et al., CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study, Exp Ther Med, vol.4, pp.435-441, 2012.

J. Li, X. Y. Zhong, Z. Y. Li, J. F. Cai, L. Zou et al., CD133 expression in osteosarcoma and derivation of CD133+ cells, Mol Med Rep, vol.7, pp.577-584, 2013.

T. Fujiwara, T. Katsuda, K. Hagiwara, N. Kosaka, Y. Yoshioka et al., Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells, Stem Cells, vol.32, pp.959-973, 2014.

P. M. Glumac and A. M. Lebeau, The role of CD133 in cancer: a concise review, Clin Transl Med, vol.7, p.18, 2018.

J. Tian, X. Li, M. Si, T. Liu, and J. Li, CD271+ osteosarcoma cells display stem-like properties, PloS one, vol.9, p.98549, 2014.

D. Zhang, Q. Zhao, H. Sun, L. Yin, J. Wu et al., Defective autophagy leads to the suppression of stem-like features of CD271+ osteosarcoma cells, J Biomed Sci, vol.23, p.82, 2016.

V. Saini, C. D. Hose, A. Monks, K. Nagashima, B. Han et al., Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma, PLoS One, vol.7, p.41401, 2012.

Y. H. Lee, H. W. Yang, L. C. Yang, M. Y. Lu, L. L. Tsai et al., Hu FW (2107) DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells, Oncol Lett, vol.14, pp.171-179

X. T. Qi, Y. L. Li, Y. Q. Zhang, T. Xu, B. Lu et al., KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells, Acta Pharmacol

Y. Li, M. Xian, B. Yang, M. Ying, and Q. He, Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells, Stem Cell Reports, vol.8, pp.1617-1629, 2017.

S. R. Martins-neves, W. E. Corver, D. I. Paiva-oliveira, . Van-den-akker, . Be et al., Osteosarcoma stem cells have active Wnt/beta-catenin and overexpress SOX2 and KLF4, J Cell Physiol, vol.231, pp.876-886, 2016.

H. Y. Xu, W. Fang, Z. W. Huang, J. C. Lu, Y. Q. Wang et al., Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling, Eur Rev Med Pharmacol Sci, vol.21, pp.4516-4528, 2017.

T. Chano, H. Kita, S. Avnet, S. Lemma, and N. Baldini, Prominent role of RAB39A-RXRB axis in cancer development and stemness, Oncotarget, vol.9, pp.9852-9866

X. Xi, Q. Wu, Y. Bao, X. Zhong, X. Dai et al., Overexpression of TBL1XR1 confers tumorigenic capability and promotes recurrence of osteosarcoma, Eur J Pharmacol in press

F. Liu, L. Li, Y. Li, X. Ma, X. Bian et al., Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV, Int J Oncol, vol.53, pp.2010-2020, 2018.

L. Yu, S. Liu, C. Zhang, B. Zhang, B. M. Simoes et al., Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity, Oncotarget, vol.4, pp.2326-2364, 2013.

J. Lu, G. Song, Q. Tang, J. Yin, C. Zou et al., MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1, Oncogene, vol.36, pp.231-241, 2017.

R. M. Zhang, T. Tang, H. M. Yu, and X. D. Yao, LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling, Biochem Biophys Res Commun, vol.507, pp.260-266, 2018.

Y. Zou, Y. Huang, J. Yang, J. Wu, and C. Luo, 2017) miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity, Mol Med Rep, vol.15, pp.1631-1637

D. Zhao, Y. Chen, S. Chen, C. Zheng, J. Hu et al., MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN, Tumour Biol, vol.39, p.1010428317705341, 2017.

X. Guo, L. Yu, Z. Zhang, G. Dai, T. Gao et al., negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1, Cancer Cell Int, vol.17, p.29, 2017.

D. Fiore, R. Drago-ferrante, R. Pentimalli, F. , D. Marzo et al., Let-7d miRNA shows both antioncogenic and oncogenic functions in osteosarcoma-derived 3AB-OS cancer stem cells, J Cell Physiol, vol.231, pp.1832-1841, 2016.

L. Noce, M. Paino, F. Mele, L. Papaccio, G. Regad et al., HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy, J Exp Clin Cancer Res, vol.37, p.296, 2018.

C. P. Gibbs, V. G. Kukekov, J. D. Reith, O. Tchigrinova, O. N. Suslov et al., Stem-like cells in bone sarcomas: implications for tumorigenesis, Neoplasia, vol.7, pp.967-976, 2005.

H. Fujii, K. Honoki, T. Tsujiuchi, A. Kido, K. Yoshitani et al., Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines, Int J Oncol, vol.34, pp.1381-1386, 2009.

S. R. Martins-neves, A. O. Lopes, A. Do-carmo, A. A. Paiva, P. C. Simoes et al., Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line, BMC Cancer, vol.12, p.139, 2012.

M. Tellez-gabriel, C. Charrier, B. Royer, B. Mullard, M. Brown et al., Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip, Eur J Cell Biol, vol.96, pp.110-118, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01466071

S. Avnet, D. Pompo, G. Chano, T. Errani, C. Ibrahim-hashim et al., Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-?B activation, Int J Cancer, vol.140, pp.1331-1345, 2017.

M. Cortini, S. Avnet, and N. Baldini, Mesenchymal stroma: role in osteosarcoma progression, Cancer Lett, vol.405, pp.90-99, 2017.

S. R. Baglio, T. Lagerweij, M. Pérez-lanzón, X. D. Ho, N. Léveillé et al., Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression, Clin Cancer Res, vol.23, pp.3721-3733, 2017.

H. Zhang, H. Wu, J. Zheng, P. Yu, L. Xu et al., , 2013.

, Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma, Stem Cells, vol.31, pp.433-479

A. Lamora, J. Talbot, M. Mullard, B. Royer, B. Redini et al., TGF-? Signaling in bone remodeling and osteosarcoma progression, J Clin Med, vol.5, issue.11, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01701177

S. R. Martins-neves, D. I. Paiva-oliveira, P. M. Wijers-koster, A. J. Abrunhosa, C. Fontes-ribeiro et al., Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling, Cancer Lett, vol.370, pp.286-95, 2016.

A. Vallée and Y. Lecarpentier, Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT/?-catenin pathway in chronic Inflammation and oxidative stress during carcinogenesis, Front Immunol, vol.9, p.745, 2018.

A. Sharma and E. Capobianco, Immuno-Oncology Integrative Networks: Elucidating the Influences of Osteosarcoma Phenotypes, Cancer Inform, vol.16, p.1176935117721691, 2017.

C. Dumars, J. M. Ngyuen, A. Gaultier, R. Lanel, N. Corradini et al., Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, pp.78343-78354, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466103

S. Théoleyre, K. Mori, B. Cherrier, N. Passuti, F. Gouin et al., Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma, BMC Cancer, vol.5, p.123, 2005.

A. J. Saraf, J. M. Fenger, and R. D. Roberts, Osteosarcoma: Accelerating Progress Makes for a Hopeful Future, Front Oncol, vol.8, p.4, 2018.

M. R. Makena, A. Ranjan, V. Thirumala, and A. Reddy, Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance, Biochim Biophys Acta Mol

J. M. Gonçalves, C. Silva, E. Rivero, and M. Cordeiro, Inhibition of cancer stem cells promoted by Pimozide, Clin Exp Pharmacol Physiol

L. Peng and D. Jiang, Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition, PLoS One, vol.13, 2018.

Y. Miao, H. Zhang, Y. Pan, J. Ren, M. Ye et al., Single-walled carbon nanotube: One specific inhibitor of cancer stem cells in osteosarcoma upon downregulation of the TGF?1 signaling, Biomaterials, vol.149, pp.29-40, 2017.

S. R. Martins-neves, D. I. Paiva-oliveira, C. Fontes-ribeiro, J. Bovée, A. M. Cleton-jansen et al., IWR-1, a tankyrase inhibitor, attenuates Wnt/?-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft, 2018.

H. Y. Xu, W. Fang, Z. W. Huang, J. C. Lu, Y. Q. Wang et al., Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling, Eur Rev Med Pharmacol Sci, vol.21, issue.20, pp.4516-4528, 2017.

D. Shang, J. Wu, L. Guo, Y. Xu, L. Liu et al., Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2, Int J Oncol, vol.50, pp.1848-1856, 2017.

D. I. Paiva-oliveira, S. R. Martins-neves, A. J. Abrunhosa, C. Fontes-ribeiro, and C. Gomes, Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells, Cancer Chemother Pharmacol, vol.81, pp.49-63, 2018.

F. Chen, Y. Zeng, X. Qi, Y. Chen, Z. Ge et al., Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipidpolymer nanoparticles to both osteosarcoma cells and cancer stem cells, Nanomedicine, vol.14, pp.2115-2127, 2018.

H. Qu, Y. Xue, W. Lian, C. Wang, J. He et al., Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling, Life Sci, vol.207, pp.253-264, 2018.

G. N. Yan, X. F. Tang, X. C. Zhang, T. He, Y. S. Huang et al., TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway, Oncotarget, vol.8, pp.85628-85641, 2017.

W. Zhang, J. M. Zhao, J. Lin, C. Z. Hu, W. B. Zhang et al., Adaptive fibrogenic reprogramming of osteosarcoma stem cells promotes metastatic growth, Cell Rep, vol.24, pp.1266-1277, 2018.

G. Mesiano, G. Grignani, E. Fiorino, V. Leuci, R. Rotolo et al., Cytokine induced killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy, Oncoimmunology, vol.7, p.1465161, 2018.

S. P. D'angelo, L. Melchiori, M. S. Merchant, D. Bernstein, J. Glod et al., Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma. Cancer Discov, vol.8, pp.944-957, 2018.